Therapeutic Area | MeSH |
---|---|
infections | D007239 |
skin and connective tissue diseases | D017437 |
Brand Name | Status | Last Update |
---|---|---|
bactroban | New Drug Application | 2012-10-24 |
centany | 2007-02-13 | |
dermacinrx clorhexacin | unapproved drug other | 2024-12-13 |
dermawerx surgical plus pak | ANDA | 2015-12-09 |
levocetirizine dihydrochloride 2% / mupirocin 2% / triamcinolone acetonide 0.025% | unapproved drug other | 2019-05-14 |
lidocaine 2% / mupirocin 2% | unapproved drug other | 2019-05-14 |
metronidazole 1% / mupirocin 2% / | unapproved drug other | 2019-05-14 |
metronidazole 1% / mupirocin 2% | unapproved drug other | 2019-05-14 |
mupirocin | ANDA | 2025-03-25 |
nusurgepak surgical prep/carepak | ANDA | 2020-06-22 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
bacterial infections | — | D001424 | A49 |
impetigo | EFO_1000714 | D007169 | L01 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Infections | D007239 | EFO_0000544 | — | — | — | — | 2 | 1 | 3 |
Communicable diseases | D003141 | — | — | — | — | — | 2 | 1 | 3 |
Staphylococcal infections | D013203 | — | A49.01 | — | — | — | 2 | 1 | 3 |
Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | 1 | — | 1 |
Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | — | 1 | — | 1 |
Staphylococcus aureus | D013211 | NCBITaxon_1280 | — | — | — | — | 1 | — | 1 |
Cross infection | D003428 | — | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cellulitis | D002481 | EFO_0003035 | L03.90 | — | — | — | — | 2 | 2 |
Wound healing | D014945 | GO_0042060 | — | — | — | — | — | 1 | 1 |
Bacterial infections | D001424 | — | A49 | — | — | — | — | 1 | 1 |
Infectious skin diseases | D012874 | — | — | — | — | — | — | 1 | 1 |
Bacterial skin diseases | D017192 | — | — | — | — | — | — | 1 | 1 |
Impetigo | D007169 | EFO_1000714 | L01 | — | — | — | — | 1 | 1 |
Community-acquired infections | D017714 | — | — | — | — | — | — | 1 | 1 |
Abscess | D000038 | EFO_0003030 | — | — | — | — | — | 1 | 1 |
Folliculitis | D005499 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Mupirocin |
INN | mupirocin |
Description | Mupirocin is an alpha,beta-unsaturated ester resulting from the formal condensation of the alcoholic hydroxy group of 9-hydroxynonanoic acid with the carboxy group of (2E)-4-[(2S)-tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoic acid in which the tetrahydropyranyl ring is substituted at positions 3 and 4 by hydroxy groups and at position 5 by a {(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl group. Originally isolated from the Gram-negative bacterium Pseudomonas fluorescens, it is used as a topical antibiotic for the treatment of Gram-positive bacterial infections. It has a role as a bacterial metabolite, an antibacterial drug and a protein synthesis inhibitor. It is a monocarboxylic acid, a member of oxanes, an epoxide, a secondary alcohol, a triol and an alpha,beta-unsaturated carboxylic ester. It is a conjugate acid of a mupirocin(1-). |
Classification | Small molecule |
Drug class | t-RNA synthetase inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | C/C(=C\C(=O)OCCCCCCCCC(=O)O)C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O |
PDB | — |
CAS-ID | 12650-69-0 |
RxCUI | — |
ChEMBL ID | CHEMBL719 |
ChEBI ID | 7025 |
PubChem CID | 446596 |
DrugBank | DB00410 |
UNII ID | D0GX863OA5 (ChemIDplus, GSRS) |